Delving into the Latest Updates on WTS-005 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersSkin and Musculoskeletal Diseases

Active Indication

Breast CancerHepatocellular CarcinomaHER2-positive gastric cancer

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Hangzhou Wutong Tree Pharmaceutical Co., Ltd.

Active Organization

Hangzhou Wutong Tree Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Main objectives 1. To evaluate the safety and tolerability of WTS-005 tablets in patients with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) and the recommended dose for phase II (RP2D). Secondary objectives 1. To evaluate the preliminary anti-tumor efficacy of WTS-005 tablets. 2. To evaluate the pharmacokinetic characteristics of WTS-005 tablets in patients with advanced solid tumors.

Start Date-

Sponsor / Collaborator

Hangzhou Wutong Tree Pharmaceutical Co., Ltd.

CTR20230396

/ SuspendedPhase 1

评价WTS-005片在晚期实体瘤癌患者中的安全性、耐受性、药代动力学特征及初步有效性的开放、多中心、剂量递增与扩展的I期临床研究。

[Translation] An open, multicenter, dose-escalation and expansion Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of WTS-005 tablets in patients with advanced solid tumors.

主要目的 1.评价WTS-005片在晚期实体瘤患者的安全性和耐受性。 2.确定最大耐受剂量（MTD）及II期推荐剂量（RP2D）。次要目的 1.评价WTS-005片的初步抗肿瘤疗效。 2.评价WTS-005片在晚期实体瘤患者体内的药代动力学特征。

[Translation]

Main objectives 1. To evaluate the safety and tolerability of WTS-005 tablets in patients with advanced solid tumors. 2. To determine the maximum tolerated dose (MTD) and the recommended dose for phase II (RP2D). Secondary objectives 1. To evaluate the preliminary anti-tumor efficacy of WTS-005 tablets. 2. To evaluate the pharmacokinetic characteristics of WTS-005 tablets in patients with advanced solid tumors.

Start Date07 Jun 2023

Sponsor / Collaborator

Hangzhou Wutong Tree Pharmaceutical Co., Ltd.

100 Clinical Results associated with WTS-005

Login to view more data

100 Translational Medicine associated with WTS-005

Login to view more data

100 Patents (Medical) associated with WTS-005

Login to view more data

100 Deals associated with WTS-005

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	China	Hangzhou Wutong Tree Pharmaceutical Co., Ltd.	07 Jun 2023
Breast Cancer	Phase 1	China	Hangzhou Wutong Tree Pharmaceutical Co., Ltd.	14 Feb 2023
Hepatocellular Carcinoma	Phase 1	China	Hangzhou Wutong Tree Pharmaceutical Co., Ltd.	14 Feb 2023
HER2-positive gastric cancer	Phase 1	China	Hangzhou Wutong Tree Pharmaceutical Co., Ltd.	14 Feb 2023